Arcus Biosciences, Inc. (RCUS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$201.0M
Cash & Equivalents
$138.0M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$3,637M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
| 2026-10-31 | Phase2 Readout | — |
| 2026-11-01 | Phase1 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
| 2026-12-01 | Phase1 Readout | — |
| 2027-01-01 | Phase2 Readout | — |
| 2027-04-01 | Phase2 Readout | — |
| 2027-04-30 | Phase2 Readout | — |
| 2027-05-01 | Phase2 Readout | — |
| 2027-05-01 | Phase1 Readout | — |
Active Clinical Trials (20)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05211895 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants Wi... | PHASE3 | Recruiting | 860 |
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Car... | PHASE3 | Recruiting | 720 |
| NCT07000149 | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment fo... | PHASE3 | Active Not Recruiting | 1,116 |
| NCT06608927 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ad... | PHASE3 | Active Not Recruiting | 610 |
| NCT04791839 | Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patient... | PHASE2 | Active Not Recruiting | 30 |
| NCT05633667 | Study of Novel Treatment Combinations in Patients With Lung Cancer | PHASE2 | Active Not Recruiting | 192 |
| NCT05915442 | Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer | PHASE2 | Recruiting | 23 |
| NCT05688215 | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable... | PHASE2 | Recruiting | 56 |
| NCT06048484 | Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma | PHASE2 | Recruiting | 60 |
| NCT05024097 | A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemot... | PHASE2 | Recruiting | 43 |
| NCT05724563 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | PHASE2 | Active Not Recruiting | 58 |
| NCT05130177 | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | PHASE2 | Active Not Recruiting | 8 |
| NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | PHASE2 | Recruiting | 32 |
| NCT03821246 | Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | PHASE2 | Recruiting | 68 |
| NCT04104672 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies | PHASE1 | Active Not Recruiting | 196 |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | PHASE1 | Active Not Recruiting | 40 |
| NCT04656535 | AB154 Combined With AB122 for Recurrent Glioblastoma | PHASE1 | Active Not Recruiting | 46 |
| NCT06120075 | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | PHASE1 | Active Not Recruiting | 91 |
| NCT05536141 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | PHASE1 | Recruiting | 362 |
| NCT07641881 | A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Part... | PHASE1 | Recruiting | 24 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.